GE MEDICAL SYSTEMS

GE HealthCare leads a $27.8 million initiative with 29 partners to expand theranostics, aiming to broaden delivery to community sites and focus on diseases like sarcomas and cancers of the prostate, ovaries, and pancreas. The project, Thera4Care, aims to improve healthcare system readiness for precision medicine by expanding isotope manufacturing, developing next-generation imaging scanners, and creating AI-based clinical tools.

Aiforia joins EU-funded Thera4Care project to advance precision medicine, focusing on AI solutions for clinical decision support and predictive modeling.

GE HealthCare leads Thera4Care, a €25.3 million initiative to revolutionize theranostics in Europe, aiming to broaden patient access to personalized cancer treatments by standardizing and scaling the production and use of key isotopes and integrating AI for better diagnostics and therapy.

The report on the Personalized Medicine Market by Vantage Market Research highlights market size, forecast, opportunities, key drivers, regulatory scenario, industry trends, new product approvals, competitive landscape, and regional analysis. Key players include Abbott Laboratories, Merck & Co., AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Amgen, Bayer, Eli Lilly, Illumina, Danaher, QIAGEN, 23andMe, Roche, Thermo Fisher Scientific, GE Healthcare, and Precision Biologics. Market types cover diagnostics, therapeutics, medical care, and nutrition, while applications include oncology, neurology, cardiology, antiviral, psychiatry, immunology, and others. The report also examines COVID-19's impact on the market.

GE HealthCare's Phase I clinical trial of a novel manganese-based MRI contrast agent showed it was well tolerated with no serious adverse events, potentially offering an alternative to gadolinium-based agents and addressing environmental concerns.

GE HealthCare accelerates precision medicine cluster in Chengdu, leveraging the city's open environment and industrial advantages, aiming to build a global supply chain in western China.

GE HealthCare's MIM Software received FDA 510(k) clearance for MIMneuro, enabling Centiloid scaling to analyze amyloid plaque density via PET imaging, aiding Alzheimer’s diagnosis and treatment.

2024 saw significant federal and medtech focus on women's health, including Biden's initiatives, Jill Biden's $100M research funding, and medtech advancements like Edwards Lifesciences' TAVI outcomes for women, Melodi Health's absorbable mesh for breast cancer, Cairn Surgical's breast cancer locator, GE HealthCare's female-specific imaging, Virtual Incision's MIRA robot for hysterectomies, Hologic's AI cervical cytology system, Moon Surgical's Maestro robot for gynecological procedures, and Lumicell's breast cancer visualization system.